ストックスクリーナーアプリを入手
1.19
3.25%
-0.04
アフターアワーズ：
1.18
-0.01
-0.84%
Spero Therapeutics Inc (SPRO) 最新ニュース
Spero Therapeutics, Inc.: Shareholders Board Members Managers and Company Profile | US84833T1034 - marketscreener.com
Diluted shares outstanding of Spero Therapeutics, Inc. – BIVA:SPRO - TradingView
Long term debt to total assets ratio of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Net current asset value per share of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights - GuruFocus
SPRO Looks 14.8% Overvalued on GF Value™ as FDA Approval Spurs I - GuruFocus
Spero Therapeutics Q2 Earnings Call Highlights - MarketBeat
SPRO: FDA approval, immunology pivot, and $105M financing extend cash runway into 2029 - TradingView
Earnings call transcript: Spero Therapeutics posts small q2 2026 EPS beat - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Is Spero Therapeutics Inc (SPRO) a Smart Investment Post Q2 Earnings? GF Score: 69/100, 13.3% Overvalued - GuruFocus
SPRO: FDA approval of Utebzi and $105M financing position the company for long-term growth - tradingview.com
Spero Therapeutics 2Q 2026: Revenue $0M, EPS $(0.16) — 10-Q Summary - TradingView
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... By GuruFocus - Investing.com Canada
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Spero Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Equity awards for Spero Therapeutics (SPRO) chief medical officer - Stock Titan
Spero Therapeutics CMO Debra Zack files initial beneficial ownership statement - Bitget
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
SPRO Q2'26 Earnings: EPS estimate is (0.17) USD - TradingView
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - The Manila Times
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update ... - Caledonian Record
Spero Therapeutics to discuss drug pipeline on Aug. 12 - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Spero Therapeutics (SPRO) Holds Steady at $1.17 as Shares Consolidate in a Tight RangeHigh Volume Stocks - dars.gov.et
Spero Therapeutics, Inc. Revenue Breakdown – NASDAQ:SPRO - TradingView
SPRO|Spero Therapeutics Inc|Price:1.170|Chg%:-0.020 - TradingKey
Spero Therapeutics Appoints Dr. Debra Jeske Zack Chief Medical Officer to Lead SP001 Development - citybiz.co
Spero Therapeutics names Debra Zack as chief medical officer - Investing.com
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Spero Therapeutics names Debra Zack as chief medical officer By Investing.com - Investing.com Canada
Spero's Phase 2-Ready Antibody Has a New Clinical Lead - Stock Titan
Spero Therapeutics Inc (SPRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics (SPRO) Hovers Near Support After Modest DeclineCommon Gap - dars.gov.et
Spero Therapeutics Inc (SPRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Spero Therapeutics Inc (SPRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200-Day Moving AverageShould You Sell? - MarketBeat
SPRO|Spero Therapeutics Inc|Price:1.195|Chg%:-0.035 - TradingKey
Spero Therapeutics Inc (SPRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spero Therapeutics Secures $105 Million Royalty Financing and Exclusive License for SP001 - Global Legal Chronicle
SPRO stock holds its ground on Spero Therapeutics financing and pipeline - Ad-hoc-news.de
Enterprise value to EBITDA forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Enterprise value to revenue forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to earnings forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to book forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to sales forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Innovent licenses IBI355 rights to Spero for up to $1.1bn - Yahoo Finance
Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Lice - GuruFocus
Spero Therapeutics secures $105 million royalty financing - The Pharma Letter
Spero licenses anti-CD40L antibody from Innovent for $1.1bn By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Secures Exclusive License for IBI355 - GuruFocus
Spero Therapeutics: 'Buy' Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO) - Seeking Alpha
Asia deal flurry draws AZ, Spero to $1B+ Dizal, Innovent assets - bioworld.com
Spero licenses anti-CD40L antibody from Innovent for $1.1bn - Investing.com UK
Spero signs $1.1 billion SP001 licensing deal - grafa.com
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion - Reuters
Spero Therapeutics secures $105m financing for drug development By Investing.com - Investing.com India
Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Licensing Agreement - GuruFocus
Spero Therapeutics Secures $105 Million Royalty Financing to Advance Immunology Pipeline - citybiz
Spero in-licenses Innovent’s antibody therapy (SPRO:NASDAQ) - Seeking Alpha
Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing - Moomoo
Spero Therapeutics (SPRO) Secures $105M Financing to Advance Imm - GuruFocus
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):